For example, Dicembrini et al. found no significant association between SGLT2 inhibitors and breast cancer [24], while subsequent meta-analyses by Spiazzi et al. and Xu et al. extended the analysis to other tumor types (endometrial and uterine) and still observed no significant risks [25, 26]. The gene discussed is SLC5A2; the disease is breast carcinoma.